Serotonin receptors, including 5‐HT3 and 5‐HT4, guanylate cyclase‐C, and several purinergic receptors including P2X3 and P2Y, are potential targets under investigation as gut motility or visceral pain modulators for the treatment of IBS [26]. This evidence concerns the gene P2RX3 and irritable bowel syndrome.